Our data support the implementation of Hsp90 inhibition in the treatment of relapsed DLBCL in combination with current cisplatin-based treatment regimens, to sensitize cisplatin insensitive cells to treatment. This evidence concerns the gene HSP90AA1 and diffuse large B-cell lymphoma.